This study is in progress, not accepting new patients
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at Burbank, California and other locations
- Dates
- study startedcompletion around
Description
Summary
Official Title
Keywords
Eligibility
Locations
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Gilead Sciences
- Links
- Gilead Clinical Trials Website Sign up for this study
- ID
- NCT05382286
- Phase
- Phase 3 research study
- Study Type
- Interventional
- Participants
- About 443 people participating
- Last Updated